Physician profile
Lance Lasner
NPI 1710088299
$15,379.05
in general payments reported to CMS, 2019-2025
38 companies · $4,677 in 2025
The $4,677 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $558 · 2021: $1,391 · 2022: $2,313 · 2023: $2,525 · 2024: $2,783 · 2025: $4,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,854 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,853.76 |
| Education | $131.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,079.29 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,323.96 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $1,499.18 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $1,447.49 | 2019-2025 | Livdelzi |
| Ardelyx, INC. | $1,134.11 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $948.11 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $905.43 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $679.72 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $574.27 | 2022-2025 | |
| Janssen Biotech, INC. | $402.56 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Madrigal Pharmaceuticals | $329.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $290.51 | 2022-2025 | |
| Lilly USA, LLC | $251.39 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Nestle Healthcare Nutrition INC. | $204.92 | 2021-2023 | |
| Vivus LLC | $182.52 | 2023-2025 | Qsymia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $145.09 | 2025 | |
| Braintree Laboratories, INC. | $142.90 | 2019-2025 | Suflave, Sutab |
| Celltrion USA INC. | $121.56 | 2024-2025 | Vegzelma, Zymfentra |
| Covidien Lp | $97.67 | 2019 | |
| Daiichi Sankyo INC. | $81.17 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $80.42 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $78.17 | 2025 | Zenpep |
| Novo Nordisk INC | $63.38 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $59.42 | 2023-2024 | Dupixent |
| Boston Scientific Corporation | $29.24 | 2019-2023 | |
| Evoke Pharma, INC. | $28.24 | 2021-2022 | |
| Enterra Medical, INC. | $27.45 | 2024 | |
| Alfasigma USA, INC. | $25.97 | 2020 | |
| Redhill Biopharma INC. | $23.07 | 2022 | |
| Ethicon US, LLC | $21.54 | 2021 | |
| Horizon Therapeutics Plc | $20.93 | 2022 | |
| Organon LLC | $17.61 | 2023 | Hadlima |
| Capsovision, INC. | $17.42 | 2023 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $14.01 | 2020 | |
| Olympus America INC. | $13.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 | |
| Allergan, INC. | $5.57 | 2019 | |
| Travere Therapeutics, INC. | $1.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Lasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.